2025-01-11 IDOPRESS
HANGZHOU,China,Jan. 10,2025 -- BEST Inc. (NYSE: BEST) ("BEST" or the "Company"),a leading integrated smart supply chain solutions and logistics services provider in China and Southeast Asia,today announced that,on January 6,2025,the Company received a notice from the New York Stock Exchange (the "NYSE") Regulation stating that it is not in compliance with the NYSE's continued listing requirements under the timely filing criteria pursuant to Section 802.01E of the NYSE Listed Company Manual (the "Continued Listing Criteria") as a result of the Company's failure to timely file its Form 6-K containing semi-annual financial information for the half year ended June 30,2024 (the "1H 2024 6-K") with the U.S. Securities and Exchange Commission (the "SEC").
The Company has not yet filed the 1H 2024 6-K with the SEC because it has focused its resources on its previously announced going private transaction. Upon completion of the privatization,the Company will become a privately held company and its Class A ordinary shares would no longer be listed on the NYSE.
ABOUT BEST INC.
BEST Inc. (NYSE: BEST) is a leading integrated smart supply chain solutions and logistics services provider in China and SEA. Through its proprietary technology platform and extensive networks,BEST offers a comprehensive set of logistics and value-added services,including freight delivery,supply chain management and global logistics services. BEST's mission is to empower business and enrich life by leveraging technology and business model innovation to create a smarter,more efficient supply chain. For more information,please visit: http://www.best-inc.com/en/.
Cangxi County Holds 2026 New Year's Cultural Performance for the Public
The First Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
The Second Series of the World Chinese Medicine Forum in 2025 Concludes Successfully
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Singapore College of Traditional Chinese Medicine Sign Strategic Cooperation Framework Agreement on TCM Education and Exchange
Tianjiang Pharmaceutical, a Subsidiary of China TCM, Participates in the 4th CACM Specialized Disease Collaboration Platform Annual Conference & 10th Jiangsu Traditional Chinese Medicine Academic Conference
Tianjiang Pharmaceutical, a Subsidiary of China TCM, and Federation of Chinese Medicine & Acupuncture Societies of Australia Sign Strategic Cooperation Framework Agreement
©copyright 2009-2020 Singapore Info Map